MRI scans after stem cell transplant for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at using MRI scans to check for remaining disease in your bones and to measure fat in the bone marrow after a stem cell transplant for multiple myeloma. It aims to see if these MRI readings can help predict how well you respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have been newly diagnosed with multiple myeloma
- You need to be eligible for and have received a stem cell transplant
- Your first treatment must have been a four-drug combination that includes a CD38-targeting medicine
- You must have had an MRI scan after your transplant (or after your second transplant if you had two) and before starting maintenance therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This study tests a new way to make MRI scans look like CT scans to find bone damage from multiple myeloma. You may join if you have just been diagnosed or if your disease came back after strong treatments, and you need bone imaging for staging.
This trial compares two whole-body imaging scans (full-body MRI using DWI and a PET/CT scan) to see which does a better job detecting and staging active multiple myeloma. If you have been newly diagnosed or are being evaluated for suspected symptomatic myeloma, joining could help doctors learn which test is best for planning your care.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This study compares a new investigational drug (AZD0120) with a standard stem cell transplant for people with newly diagnosed multiple myeloma who have already completed initial treatment. The goal is to see if the new drug works as well as or better than the transplant in keeping the cancer from coming back.
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.